Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 28, 2022 12:23pm

163 Views

Post# 35134048

RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

The rally in ONCY share price late last week in advance of US Thanksgiving Day, and in the absence of hedge fund and MM traders for that period of time due to the holidays, their return and anti-momentum trading today further confirms that these actors are "working" the share price of this stock contrary to those who say they aren't.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland